Exclusive interviews from leading entrepreneurs, FTSE 350 CEOs, thought leaders.

In 2009, the outlook for Eli Lilly was uncertain. But a dogged commitment to R&D has shored up its future and positioned it at the forefront of pharma innovation. Pursuing organic growth is often ...

Improving macroeconomic conditions and increased political certainty point to a favourable outlook for IPO activity across ...

AI, automation and acquisitions are some of the key agenda items for respondents to our latest MT Asks. All the latest news, ...